The successful prevention, diagnosis, and clinical management of cervical cancer depend heavily on early screening. For liquid-based Papanicolaou smear screening to be effective, the clinician must have expertise in distinguishing between tissue or cell abnormalities caused by precancerous lesions and other inflammatory conditions in the cervix ([@bib17]). In addition, highly skilled technicians and pathologists must be able to interpret patient specimen slides and produce a definitive diagnosis. Such screening can be particularly challenging in resource-poor settings that lack trained clinicians and pathologists.

An objective method of interpreting cytopathic changes associated with cervical disease, known as DNA ploidy analysis, involves the numerical measurement of DNA content in the nucleus of the cell ([@bib16]; [@bib10]). Since chromosomal aneuploidy has been significantly associated with progression toward cervical carcinoma, quantification of DNA aneuploidy may serve as a prognostic marker of disease ([@bib4]; [@bib40]). This process can be computerized by machine algorithm to automate diagnosis of cervical lesions and thus implemented in population-based screening. Previous literature has suggested that DNA ploidy analysis is capable of a stand-alone testing method ([@bib39]; [@bib44]).

For automated DNA ploidy analysis to be considered as an alternative for the screening of cervical malignancies, an evaluation with regard to both quality-adjusted life expectancy and costs is needed. This study presents a comparative analysis of DNA ploidy analysis and liquid-based cytology screening in terms of the potential economic costs and clinical benefits of this new technology. Our results may have an impact on the choice of cost-effective strategies for large-scale screening programs.

Materials and methods
=====================

DNA ploidy analysis
-------------------

By definition, DNA ploidy analysis is a quantitative technique. It is one of the methods used to detect cervical cancer and its precursors. It is performed on Feulgen-stained specimens in a semi-automated manner. Unlike liquid-based cytology screening, DNA ploidy analysis is not subject to the retesting of 10% of normal specimens that is required by Clinical Laboratory Improvement Amendments 1988 regulations ([@bib42]). An abnormal specimen identified by the ploidy method would be equivalent in terms of clinical management to a result of low-grade squamous intraepithelial lesion (LSIL) in the Bethesda system for reporting cytologic results. Thus, either of these abnormal findings -- that is, abnormal DNA ploidy or LSIL result for Papanicolaou smear --- would be followed up with a diagnostic visit which typically includes colposcopy and biopsy (if required). Treatment, if needed, would occur subsequently.

Five DNA ploidy strategies were examined in this study. In a reported clinical trial, the sensitivity and specificity of the ploidy strategy were measured on the basis of five cut points for the number of aneuploid cells ([Table 1](#tbl1){ref-type="table"}) ([@bib17]). With the 1-cell cut point strategy (ploidy 1 cell strategy), the presence of at least one aneuploid cell in a given slide rendered it an abnormal specimen. Similarly, the DNA ploidy cytology at n-cell cut point (n could be any whole number from 1 to 5) designated a specimen as abnormal if n aneuploid cells were found in a given slide; the terminology 'ploidy n cell strategy\' is used for these scenarios.

Comparators
-----------

In our study, we assessed the cost-effectiveness of seven strategies: the liquid-based Papanicolaou smear, the five DNA ploidy strategies involving the five cut points described above, and a no screening strategy (as an anchoring strategy). We included 'no screening\' as an anchoring strategy only for purposes to determine if DNA ploidy is cost-effective compared to this alternative in the economic evaluation. Our intention was to make a primary comparison of DNA ploidy to the usual care strategy (i.e., Papanicolaou smear screening). We only would make a comparison of DNA ploidy analysis to the anchoring 'no screening\' option if it were to be shown that the usual care strategy is not cost-effective compared to DNA ploidy analysis.

The starting age for screening was 21 years, as recommended by the current guidelines from the U.S. Preventive Services Task Force ([@bib1]). The total cost encompassed four stages in cervical cancer care (screening, diagnosis, detection, and treatment). We evaluated effectiveness in terms of quality-adjusted life-years (QALYs). The comparison was based on the incremental cost-effectiveness ratio (ICER), defined as the additional cost of a strategy divided by its additional effectiveness compared with its next best strategy. We used a willingness-to-pay threshold of \$50 000/QALY ([@bib45]) for assessing cost-effectiveness. We discounted the costs and the effectiveness at the same standard rate of 3% per annum.

Decision-analytic model
-----------------------

We used a previously published state-transition Markov model to simulate the natural history of human papillomavirus (HPV) infection and its potential development into cervical precancer or cancer. This model was first developed by investigators at Duke University ([@bib32]; [@bib34]; [@bib3]) and hereafter will be referred to as the 'Duke model.\' A hypothetical cohort of females moved through health states using a cycle length of 1 year. A total of 20 health states were used: Well, Benign Hysterectomy, Undetected HPV, Detected HPV, LSIL, High-Grade Squamous Intraepithelial Lesions (HSIL), Unknown Cancer (stages I-IV), Detected Cancer (stages I-IV), Cancer Survivor (stages I-IV), Death from Cervical Cancer, and Death from Other Causes. From the literature or previous published models of cervical cancer screening, we derived estimates of the regression and progression through the precancerous stages ([@bib11]; [@bib13]), HPV incidence rates adjusted by age ([@bib28]; [@bib20]; [@bib33]), age-specific prevalence of HPV infection ([@bib19]; [@bib25]; [@bib27]; [@bib20]), and rates of progression and regression of squamous intraepithelial lesions ([@bib41]). The estimation for survival rates for cervical cancer after diagnosis by stage was based on patient care evaluation data obtained from the American College of Surgeons (1990) and patterns-of-care studies ([@bib21]). Having a hysterectomy for benign disease affects the chance of developing cervical cancer; thus, the model included the age-specific hysterectomy rates from the National Hospital Discharge Survey ([@bib29]) and Maryland discharge data ([@bib26]). The mortality rates for deaths due to other causes were derived by subtracting age-specific cervical cancer mortality rates from the general mortality rates reported in the U.S. life tables ([@bib35]). Additionally, the natural history parameters were adjusted to determine the age-specific incidence of cervical cancer in an unscreened population ([@bib18]).

For the screening and follow-up strategies, a woman would experience a sequential process beginning with either the Papanicolaou smear or ploidy screening, followed by, if warranted, diagnosis with colposcopy and appropriate treatment: loop electrosurgical excision procedure (LEEP) for HSIL, or surgery and radiation for cancer. Key assumptions included the following: (1) 10% of the normal Papanicolaou smears were retested, (2) women were compliant with clinical treatment recommendations, and (3) after the cancer treatment, a woman could only become a survivor after 5 years, die of cervical cancer, or die of other causes.

Our study made enhancements to the Duke model in order to reflect updated clinical practice. First, we separated colposcopy and biopsy as two individual procedures (no longer a combined process) to allow for the possibility that no biopsy would occur after a normal colposcopy result. This would yield a slight reduction in cost. Second, we incorporated the findings from our work to better reflect the accuracy of colposcopy ([@bib5]). Third, if a woman had a Papanicolaou smear result of atypical squamous cells of undetermined significance (ASC-US) and a normal colposcopy result, we assumed that two additional follow-up visits over a 1-year period would also be required ([@bib7]; [@bib22]). Fourth, the sensitivity and specificity for all screening and diagnostic tests were updated based on recently published studies ([@bib15]; [@bib17]; [@bib14]). Fifth, we accounted for the clinical impact of HPV vaccination in reducing the prevalence and incidence of HPV infection and of progression into cervical neoplasia by a reduction factor. We assumed that as many as 67% of the women entering the model had been vaccinated. Also, the vaccine helped protect 70% of the infection cases which were associated with high risk oncogenic types 16 and 18 ([@bib38]; [@bib8]). These resulted in a validated reduction factor of 47% in the incidence and prevalence of HPV infection ([@bib31]) and LSIL.

Effectiveness
-------------

We changed the effectiveness measure from life years to QALYs, which incorporates both the quality of life and the survival of the study population ([@bib36]). A value of 1 indicates perfect health and 0 indicates death. This measure was also adjusted by age and health state ([@bib15]; [@bib12]). We assumed that the QALY of a woman after a hysterectomy was equal to that of a cervical cancer survivor. We also incorporated a short-term disutility of 0.01 for treating HSIL.

Costs
-----

Economic inputs in this decision-analytic model were based on the Duke model assumptions ([@bib32]). These data were derived from both claims and secondary data sources that captured all medical services for screening, diagnosis, and treatment of cervical cancer. The MarketScan database on privately insured individuals (MEDSTAT group) was utilized to estimate the costs in the group of women aged 20--64 years. The costs incurred by the older group (65+) were calculated from Medicare\'s resource-based relative value system fee schedule, clinical laboratory fee schedule, diagnosis-related group payment rates, and ambulatory surgery center payment rates. Cost-to-charge ratio was used to differentiate the costs from charges associated with hospital and physician services. All costs were transformed to 2012 U.S. dollars using the medical care component of the consumer price index ([@bib43]) ([Table 1](#tbl1){ref-type="table"}).

Several cost parameters were modified to fit the structural changes in the model. First, we formulated the cost of a Papanicolaou smear from two published cost estimates, one for normal smears and the other for abnormal smears ([@bib15]). This single value for the Papanicolaou smear was adjusted by the proportion of normal and abnormal smears in a national survey on women screened for cervical cancer ([@bib9]). Second, we separated the cost of the biopsy and colposcopy procedures, as stated above. A cost fraction to separate these two costs from the former cost (when the biopsy and colposcopy procedures\' costs were combined) was derived from the billing data of a sample of patients from our comprehensive cancer center. Third, since the ploidy strategies are not yet practiced in the United States, the cost of the screening procedure with these strategies is unknown. Thus far, the ploidy strategies were reportedly inexpensive in the lab setting ([@bib17]; [@bib14]). We took a micro-costing approach to make an initial estimate of the costs of DNA ploidy analysis, based on a 5-year shelf life for a cytometer, an estimated cost of \$1 million, the ability to process 15 000 to 50 000 slides per year at the speed of 40 slides per hour, and inexpensive labor cost for technicians (high school diploma with short training) of \$20 per hour ([@bib14]). Then, for purposes of sensitivity analysis, we converted this cost of ploidy into a multiplicative factor as compared to the cost of the Papanicolaou smear, i.e., we estimated that the cost for ploidy analysis was approximately one-half the cost of the Papanicolaou smear procedure. In other words, the ploidy cost factor between any ploidy strategy procedure and the Papanicolaou smear procedure was assumed to be 0.5. This assumption was varied in the sensitivity analysis.

Analysis
--------

The analysis was conducted from a health-system perspective using a lifetime horizon. Our base-case analysis presented the estimated total cost, total effectiveness, and ICERs for each comparator against its next best alternative when the screening frequency was every 3 years ([@bib1]) and the ploidy cost factor was 0.5. A screening strategy was deemed as the most cost-effective strategy if it both was cost-effective under the willingness-to-pay threshold of \$50 000/QALY and had the highest effectiveness. Important parameters were chosen for the sensitivity analysis based on their potential impact on the assessment of cost-effectiveness ([Table 1](#tbl1){ref-type="table"}). In a one-way sensitivity analysis, we individually varied the selected parameters throughout their plausible ranges when the screening frequency was every 3 years and the ploidy cost factor was 0.5. A two-way sensitivity analysis investigated the cost-effectiveness rankings among comparators when the frequency of screening was varied from every 1 year, every 2 years, every 3 years, every 5 years, and every 10 years while the ploidy cost factor was varied from 0.5, 0.75, and 1.0. Although screening every 3 years is the standard, multiple intervals were included in the analysis to reflect the practice (some may screen more or less frequently than others). We ran the probabilistic sensitivity analysis with 10 000 iterations to examine the robustness of the total cost and total effectiveness of all seven strategies. The ploidy strategy that was most likely to be the most cost-effective (determined by the deterministic sensitivity analysis) was chosen as the best ploidy strategy. We then evaluated the cost-effectiveness between the best ploidy strategy and the Papanicolaou smear in a cost-effectiveness plane. Cost-effectiveness acceptability curves were used to compare all of the seven strategies across a wide range of willingness-to-pay thresholds. The probabilistic sensitivity analysis was conducted under the following assumptions: (1) probability parameters were fitted with beta distributions and cost parameters with either log-normal distributions or gamma distributions; (2) for beta and gamma distributions, the standard deviation was estimated as one-fourth of the plausible range; (3) all the distributions were independent; (4) the cost of the Papanicolaou smear was stochastically varied in a gamma distribution, and the cost of the ploidy strategy was always set as one-half of the cost of the Papanicolaou smear in the base-case. The model was programmed and the analysis was performed in TreeAge Pro 2014 software (TreeAge Software Inc., Williamstown, MA, USA).

Results
=======

Base-case analysis
------------------

In the base-case analysis, the ploidy 4 cell strategy was the only cost-effective screening strategy under the willingness-to-pay threshold of \$50 000/QALY. In comparison to the anchoring no screening strategy, screening with the ploidy 4 cell strategy increased the quality-adjusted life expectancy by 0.032 QALY and yielded an ICER of \$18 264/QALY. The Papanicolaou smear strategy was the most expensive; in addition, with a much higher ICER (\$192 502/QALY), the Papanicolaou smear strategy was found to be not cost-effective ([Table 2](#tbl2){ref-type="table"}).

Deterministic sensitivity analysis
----------------------------------

We used the screening frequency of every 3 years and the ploidy cost factor being 0.5 (as the base-case) for the one-way sensitivity analyses. For most of these analyses, the ploidy 4 cell strategy was found to be the only cost-effective strategy, with ICERs ranging from \$15 151 to approximately \$40 000 per QALY. In some extreme cases in which the specificity of ploidy 4 cell was at the lower bound or the specificity of ploidy 5 cell was at the upper bound, ploidy 5 cell became the only cost-effective strategy. The Papanicolaou smear was not cost-effective, with high ICERs of approximately \$200 000/QALY. A one-way sensitivity analysis with the ploidy cost factor of 0.75 revealed that ploidy 4 cell was the only cost-effective strategy most of the time. Exceptionally, if the specificity of the Papanicolaou smear was as high as its upper bound, the Papanicolaou smear was the most cost-effective strategy (data not shown).

A two-way sensitivity analysis was implemented by varying the frequency of screening (every 1, 2, 3, 5, and 10 years) and the ploidy cost factor (0.50, 0.75, and 1.0). For all screening strategies, the ICERs were smaller when the screening was done less frequently. Further, increasing the ploidy cost factor resulted in increases in the ICERs. For example, at the same screening frequency of every 2 years, the ICERs for the ploidy 4 cell strategy increased from \$24 161 to \$30 699 per QALY when the ploidy cost factor changed from 0.50 to 0.75 and to \$37 238 when the ploidy cost factor changed to 1.0. [Table 3](#tbl3){ref-type="table"} presents the most cost-effective screening strategies for the fifteen scenarios developed by changing the screening frequency and the ploidy cost factor. In ten of the twelve scenarios (excluding screening every 10 years), the ploidy 4 cell was the only cost-effective strategy in all scenarios, and it produced ICERs ranging from \$13 157 to \$42 655. When the screening frequency was every 1 year (no longer the clinical recommendation) and the ploidy cost factor was either 0.75 or 1.0, none of the screening strategies was found to be cost-effective using the \$50 000/QALY threshold. The Papanicolaou smear strategy produced limited additional effectiveness with much greater cost, yielding ICERs as large as \$463 506. The Papanicolaou smear became the next best strategy after the ploidy 4 cell strategy in only three of the twelve scenarios. Of interest, the Papanicolaou smear strategy would be the most cost-effective if the screening frequency was every 10 years. However, with that frequency, the ploidy 4 cell strategy was cost-effective with ICERs less than \$16 000/QALY (data not shown).

Based on the results described above, the ploidy 4 cell strategy was selected as the best ploidy strategy in the deterministic sensitivity analysis.

Probabilistic sensitivity analysis
----------------------------------

In the probabilistic sensitivity analysis, the cost and the effectiveness of the seven strategies were plotted ([Figure 1](#fig1){ref-type="fig"}). The expected cost varied in increments of thousands of U.S. dollars; however, the variation in the expected effectiveness was as small as hundredths of a QALY. The seven strategies were positioned from left to right in increasing order of screening test sensitivities. The no screening strategy was the farthest to the left and apart from the other six strategies because it had the least effectiveness by a large margin. This effectiveness also remained unchanged because it did not involve any variables included in the sensitivity analysis. The Papanicolaou smear strategy was the farthest to the right since it gained the most effectiveness. It also had the widest variation both in cost and effectiveness. The cost of the Papanicolaou smear was the key driver of this strategy\'s total cost variation. The largest plausible range of the sensitivity and specificity (compared with the five ploidy strategies) of the Papanicolaou smear resulted in the most extended spread for this strategy on the effectiveness axis. The ploidy strategies and the no screening strategy had comparable cost ranges because they were influenced by the same set of cost variables (excluding the screening procedure cost). The cost-*versus*-effectiveness scatter plots for the five ploidy strategies were located next to each other and partially overlapped, since their screening test characteristics were similar.

A comparison of the Papanicolaou smear strategy to the ploidy 4 cell strategy (the best ploidy strategy determined by the deterministic sensitivity analysis) yielded ICERs primarily in the northeast quadrant of the cost-effectiveness plane ([Figure 2](#fig2){ref-type="fig"}). These ICERs had a probability of 0.91 of being larger than the willingness-to-pay threshold.

Based on the proportion of iterations for which each strategy had the highest net benefit, we investigated the probabilities of a strategy being cost-effective across a wide range of willingness-to-pay thresholds, from \$0 to \$150 000 per QALY, using cost-effectiveness acceptability curves for all seven strategies ([Figure 3](#fig3){ref-type="fig"}). The ploidy 4 cell strategy had the highest probability of being cost effective among the five ploidy strategies if the willingness-to-pay threshold was less than \$150 000/QALY. The ploidy 4 cell strategy had a higher probability of being cost-effective than the Papanicolaou smear at the willingness-to-pay threshold of \$50 000/QALY and at all other larger thresholds up to \$120 000/QALY. The cost-effectiveness of the ploidy 4 cell strategy was inferior to the Papanicolaou smear only when the willingness-to-pay increased beyond \$120 000/QALY, which may be considered as impractical in most US settings.

Discussion
==========

Our study---which is, as far as we know based on a MEDLINE literature review, the first economic analysis of DNA ploidy analysis for cervical cancer screening---shows that DNA ploidy analysis is less expensive than and similarly effective as liquid-based Papanicolaou smear screening. Within the baseline model, DNA ploidy analysis using the ploidy 4 cell strategy was demonstrated as cost-effective using the willingness-to-pay threshold of \$50 000/QALY. This result was supported by the probabilistic sensitivity analysis, in which the ploidy 4 cell strategy had the highest probability of being cost-effective under the aforementioned threshold. The sensitivity analysis also revealed that some of the other ploidy strategies (i.e., the ploidy 5 cell and ploidy 3 cell strategies) had the potential to be cost-effective if the diagnostic characteristics (i.e., sensitivity and specificity) improved. These results are supportive of previous studies showing that DNA ploidy analysis ([@bib17]) or semi-automated cytology ([@bib24]) achieves diagnostic characteristics comparable to those of the liquid-based Papanicolaou smear.

Models can guide decision-making regarding the use of new technology. In this study, we have also applied decision analysis and cost-effectiveness analysis to determine the optimal cut point for a screening test. As shown by our previous work ([@bib6]), diagnostic cut points should be determined by conducting receiver operating characteristic (ROC) curve analysis; the optimal cutoff value for a diagnostic test can be found on the ROC curve where the slope of the curve is equal to (C/B) × (1-p\[D\])/p\[D\], where p\[D\] is the disease prevalence and C/B is the ratio of the net costs of treating nondiseased individuals to the net benefits of treating diseased individuals. Therefore, cut points are identified by an arbitrary decision, or using assumptions that do not necessarily hold true, e.g., that the burden of a false-positive test is the same as the burden of a false-negative test. For instance, the comparative evaluation between DNA ploidy analysis, HPV testing, and conventional cytology presented by Guillaud *et al* ([@bib17]) used a ploidy 3 cell strategy, which was chosen as a midpoint strategy. While the results showed that DNA ploidy analysis performed comparably to conventional screening, the ploidy 3 cell strategy was chosen somewhat arbitrarily. By methodically comparing several ploidy strategies along with the liquid-based Papanicolaou smear, our decision model revealed that the ploidy 4 cell strategy results in a cost-effective screening strategy. Additionally, inherent of an appropriately designed decision analysis or cost-effectiveness analysis, our model incorporates the consequences of undertreatment (missing a case of precancer or cancer) or overtreatment (incorporating costs and some burden of treatment).

This study has limitations, including that to conduct our analyses, we adapted a cervical cancer screening model that was first published 15 years ago ([@bib34]). However, it should be recognized that we enhanced the model in several important ways (e.g., incorporating utilities and diagnostic protocols), described above, to better reflect the current standard of clinical care. At this point, we did not evaluate other screening strategies, such as triage methods using Ki67 in conjunction with HPV tests ([@bib30]). The model was kept simple to focus on DNA ploidy analysis, comparing it with two alternatives: First, although it is not an ethically viable clinical strategy, a no screening alternative was included in the analysis as benchmark for evaluating potential cost-effective strategies and for the purpose of validity check. Second, we compared DNA ploidy analysis with the standard of care, the Papanicolaou smear. This liquid-based screening standard in the United States is well established, and health care decision-making operates under a paradigm in which the alternative that provides maximum health benefits for a given level of resources is chosen ([@bib37]). Thus, it would be difficult to implement a new program that offers a lower health benefit in spite of having lower costs ([@bib23]; [@bib24]). Nevertheless, as lowering the cost of health care has taken greater priority in recent years, DNA ploidy analysis may emerge as a reasonable alternative ([@bib39]). DNA ploidy analysis may be more feasible in low-resource settings. We included less frequent screening (i.e., every 5 or 10 years) as an initial exploration of how well DNA ploidy might work in low-resource settings. However, the applicability of our results in low-resource settings cannot fully be determined without more specific information about the epidemiology of cervical cancer and its treatment in that particular setting.

In conclusion, we have shown that when DNA ploidy analysis is compared with liquid-based Papanicolaou screening, DNA ploidy analysis is a cost-effective alternative. Cervical cancer is the leading cause of cancer deaths in lower-resource settings ([@bib2]). Preventative screening programs centered on liquid-based cytology require a comprehensive and costly infrastructure. Thus, DNA ploidy analysis is a promising alternative in health care environments in which inexpensive and semi-automated services are essential.
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![Scatter plot of expected cost and quality-adjusted life expectancy for all seven strategies.](bjc201595f1){#fig1}

![**Cost-effectiveness plane for a comparison between the Papanicolaou smear and ploidy 4 cell strategies.** Abbreviation: WTP=willingness-to-pay.](bjc201595f2){#fig2}

![**Cost-effectiveness acceptability curves comparing seven strategies: no screening, Papanicolaou (Pap) smear, and the five ploidy strategies.** Curves indicate the probability that the given strategy is cost-effective at a given willingness-to-pay.](bjc201595f3){#fig3}

###### Parameters for sensitivity analyses

  **Parameter**                                   **Mean**   **Plausible range**   **Distribution**        **Source**
  ---------------------------------------------- ---------- --------------------- ------------------ -----------------------
  **Costs (2012 US\$)**                                                                              
  Colposcopy                                       \$292        \$206--\$371          Log-normal              \(8\)
  Biopsy                                           \$322        \$227--\$408          Log-normal                 
  DNA ploidy analysis                               \$44         \$44--\$88              n/a          Assumption (see text)
  Papanicolaou smear                                \$88         \$44--\$252            Gamma                \(26\)
  Treating HSIL                                    \$4996      \$2268--\$6887         Log-normal              \(8\)
  Treating cancer stage I                         \$28 914   \$15 467--\$35 962       Log-normal                 
  Treating cancer stage II                        \$44 357   \$19 228--\$47 667       Log-normal                 
  Treating cancer stage III                       \$44 357   \$19 228--\$47 667       Log-normal                 
  Treating cancer stage IV                        \$66 006   \$20 762--\$76 213       Log-normal                 
  **Screening test operating characteristics**                                                       
  Sensitivity, Papanicolaou smear                   0.84         0.69--0.88              Beta                \(26\)
  Specificity, Papanicolaou smear                   0.88         0.77--0.93              Beta                    
  Sensitivity, ploidy 1 cell                        0.74         0.67--0.79              Beta                 \(1\)
  Specificity, ploidy 1 cell                        0.82         0.79--0.83              Beta                    
  Sensitivity, ploidy 2 cell                        0.65         0.58--0.71              Beta                    
  Specificity, ploidy 2 cell                        0.90         0.88--0.92              Beta                    
  Sensitivity, ploidy 3 cell                        0.59         0.52--0.65              Beta                    
  Specificity, ploidy 3 cell                        0.93         0.92--0.94              Beta                    
  Sensitivity, ploidy 4 cell                        0.55         0.48--0.61              Beta                    
  Specificity, ploidy 4 cell                        0.95         0.93--0.96              Beta                    
  Sensitivity, ploidy 5 cell                        0.51         0.43--0.56              Beta                    
  Specificity, ploidy 5 cell                        0.95         0.93--0.96              Beta                    

###### Discounted costs, discounted quality-adjusted life expectancy (QALYs), and incremental cost-effectiveness ratios (ICERs) for the base-case analysis (screening every 3 years)

  **Strategy**          **(Sensitivity, specificity)**   **Cost (\$)**   **Incr. cost (\$)**   **Eff. (QALYs)**   **Incr. eff. (QALYs)**   **ICER (\$/QALY)**            **Notes**
  -------------------- -------------------------------- --------------- --------------------- ------------------ ------------------------ -------------------- -----------------------------
  No screening                                               \$189                                  24.685                                                                    
  Ploidy 5 cell                  (0.51; 0.95)                \$763              \$574               24.715                0.030                 \$18 821            Extended dominance
  Ploidy 4 cell                  (0.55; 0.95)                \$767              \$577               24.716                0.032                 \$18 264        [a](#t2-fn2){ref-type="fn"}
  Ploidy 3 cell                  (0.59; 0.93)                \$878              \$110               24.717                0.001                \$132 803                      
  Ploidy 2 cell                  (0.65; 0.90)               \$1044              \$167               24.718                0.001                \$148 863                      
  Ploidy 1 cell                  (0.74; 0.82)               \$1482              \$438               24.719                0.001                \$418 436            Extended dominance
  Papanicolaou smear             (0.84; 0.88)               \$1758              \$276               24.722                0.004                \$192 502        [b](#t2-fn3){ref-type="fn"}

Abbreviations: Eff= effectiveness; Incr= incremental.

Was compared with the no screening strategy because the ploidy 5 cell strategy was dominated in an extended sense.

Was compared with the ploidy 2 cell strategy because the ploidy 1 cell strategy was dominated in an extended sense.

###### The most cost-effective strategy, its next best alternative, and the Papanicolaou smear with the ICERs in a two-way sensitivity analysis with respect to screening frequency and ploidy cost factor

                             **Ploidy cost factor=0.5**                         **Ploidy cost factor=0.75**                              **Ploidy cost factor=1.0**                                                          
  -------------------------- -------------------------------------------------- -------------------------------------------------------- ---------------------------- ------------------------------ ----------------------- -------------------------------
  Screening every 1 year     Most cost-effective                                Ploidy 4 cell, \$42 655                                  Most cost-effective          Ploidy 4 cell, \$54 008        Most cost-effective     Ploidy 4 cell, \$65 361
                             Next best alternative[a](#t3-fn1){ref-type="fn"}   Ploidy 3 cell, more than 1M[b](#t3-fn2){ref-type="fn"}   Next best alternative        Ploidy 3 cell, more than 1M    Next best alternative   Ploidy 3 cell, more than 1M
                             Papanicolaou smear                                 Dominated                                                Papanicolaou smear           Dominated                      Papanicolaou smear      Dominated
  Screening every 2 years    Most cost-effective                                Ploidy 4 cell, \$24 161                                  Most cost-effective          Ploidy 4 cell, \$30 699        Most cost-effective     Ploidy 4 cell, \$37 238
                             Next best alternative                              Ploidy 3 cell, \$284 249                                 Next best alternative        Ploidy 3 cell, \$297 995       Next best alternative   Papanicolaou smear, \$276 891
                             Papanicolaou smear                                 \$463 506                                                Papanicolaou smear           \$351 416                      Papanicolaou smear      \$276 891
  Screening every 3 years    Most cost-effective                                Ploidy 4 cell, \$18 824                                  Most cost-effective          Ploidy 4 cell, \$23 270        Most cost-effective     Ploidy 4 cell, \$28 277
                             Next best alternative                              Ploidy 3 cell, \$132 803                                 Next best alternative        Ploidy 3 cell, \$139 252       Next best alternative   Papanicolaou smear, \$119 198
                             Papanicolaou smear                                 \$192 502                                                Papanicolaou smear           \$148 501                      Papanicolaou smear      \$119 198
  Screening every 5 years    Most cost-effective                                Ploidy 4 cell, \$13 157                                  Most cost-effective          Ploidy 4 cell, \$16 916        Most cost-effective     Ploidy 4 cell, \$20 674
                             Next best alternative                              Ploidy 3 cell, \$66 184                                  Next best alternative        Ploidy 3 cell, \$69 444        Next best alternative   Papanicolaou smear, \$57 543
                             Papanicolaou smear                                 \$92 403                                                 Papanicolaou smear           \$71 278                       Papanicolaou smear      \$57 543
  Screening every 10 years   Most cost-effective                                Papanicolaou smear, \$47 176                             Most cost-effective          Papanicolaou smear, \$36 727   Most cost-effective     Papanicolaou smear, \$29 655
                             Next best alternative                              n/a                                                      Next best alternative        n/a                            Next best alternative   n/a
                             Papanicolaou smear                                 \$47 176                                                 Papanicolaou smear           \$36 727                       Papanicolaou smear      \$29 655

Compared to the most cost-effective strategy.

More than \$1 000 000/QALY.
